Indications
Myozyme is indicated for long-term enzyme-replacement therapy (ERT) in patients with a confirmed diagnosis of Pompe disease (acid-?-glucosidase deficiency). In patients with late-onset Pompe disease the evidence of efficacy is limited.
Composition
- Active substance
- alglucosidase alfa
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Myozyme
- Active substance
- alglucosidase alfa
- ATC code
- A16AB07
- Therapeutic area
- Glycogen Storage Disease Type II
- Marketing authorisation holder
- Sanofi B.V.
- Status
- Authorised